Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS
0 Pogledi
• 07/16/23
0
0
Ugraditi
administrator
Pretplatnici
Visit http://www.ecancer.org for more
Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari